1. A kidney transplant recipient on stable tacrolimus 3 mg twice daily (trough 8 ng/mL) develops invasive candidiasis. The team debates whether to use fluconazole or itraconazole. Integrating the distinct CYP and transporter inhibition profiles of each azole, which prediction about tacrolimus concentrations is most accurate if itraconazole is chosen over fluconazole?
A) Itraconazole and fluconazole will produce equivalent tacrolimus concentration increases because both are azole-class CYP3A4 inhibitors; the magnitude of tacrolimus elevation is determined by the azole class mechanism, not by individual agent differences
B) Fluconazole will increase tacrolimus concentrations more than itraconazole because fluconazole inhibits both CYP2C9 and CYP3A4 simultaneously, producing a broader inhibition of tacrolimus clearance pathways than itraconazole's single-enzyme inhibition
C) Itraconazole will produce a substantially greater tacrolimus concentration increase than fluconazole — potentially 5- to 10-fold or more — because itraconazole potently inhibits both CYP3A4 and P-glycoprotein simultaneously, while fluconazole is only a moderate CYP3A4 inhibitor without significant P-glycoprotein inhibition, producing a 2- to 4-fold tacrolimus increase
D) Neither azole will significantly affect tacrolimus concentrations because tacrolimus is primarily eliminated by renal tubular secretion rather than hepatic CYP3A4 metabolism, and azole CYP interactions do not affect renally cleared calcineurin inhibitors
E) Itraconazole will decrease tacrolimus concentrations by competitively displacing tacrolimus from CYP3A4 binding sites, reducing tacrolimus metabolism only transiently before enzyme autoinduction normalizes both drug levels within 72 hours
ANSWER: C
Rationale:
Option C is correct. Tacrolimus is a substrate of both CYP3A4 and P-glycoprotein (P-gp); CYP3A4 mediates its intestinal first-pass and hepatic metabolism, while P-gp limits intestinal absorption and promotes biliary excretion. Itraconazole potently inhibits both CYP3A4 and P-gp simultaneously, removing both clearance mechanisms at once — the combined effect can increase tacrolimus blood concentrations by 5- to 10-fold or more, requiring proactive dose reduction of 50 to 75% and daily trough monitoring from the day itraconazole is initiated. Fluconazole is a moderate CYP3A4 inhibitor only — it does not significantly inhibit P-gp — producing a 2- to 4-fold tacrolimus increase that, while clinically significant and requiring management, is considerably less severe than itraconazole. This mechanistic distinction between the two agents is precisely why itraconazole carries a greater tacrolimus interaction risk and why the tacrolimus dose reduction required at itraconazole initiation is substantially larger.
Option A: Option A is incorrect; itraconazole and fluconazole have different CYP inhibition potencies and different transporter inhibition profiles. Treating them as interchangeable interaction risks because they share an azole class mechanism would lead to dangerous underdosing of tacrolimus reduction with itraconazole or excessive dose reduction with fluconazole.
Option B: Option B is incorrect; fluconazole's primary CYP interaction profile features potent CYP2C9 inhibition and moderate CYP3A4 inhibition — but CYP2C9 is not a significant metabolic pathway for tacrolimus. Tacrolimus is primarily a CYP3A4 and P-gp substrate; fluconazole's CYP2C9 inhibition does not contribute meaningfully to tacrolimus interaction, and fluconazole causes less tacrolimus elevation than itraconazole.
Option D: Option D is incorrect; tacrolimus is primarily eliminated by CYP3A4-mediated hepatic metabolism, not by renal tubular secretion. Azole-mediated CYP3A4 inhibition is the dominant mechanism of the tacrolimus interaction.
Option E: Option E is incorrect; itraconazole inhibits CYP3A4 — it does not compete for a binding site in a way that reduces tacrolimus metabolism. CYP3A4 inhibition increases tacrolimus concentrations. Enzyme autoinduction is not a property of itraconazole.
2. A 72-year-old man with atrial fibrillation on stable warfarin (INR 2.3) is started on fluconazole 200 mg daily for oropharyngeal candidiasis. Four days later his INR is 5.8 and he reports minor gum bleeding. Integrating fluconazole's CYP inhibition profile with warfarin's stereoselective pharmacology, which mechanistic explanation accounts for the magnitude and speed of this interaction?
A) Fluconazole inhibits CYP3A4, the enzyme responsible for metabolism of R-warfarin, the more pharmacologically active enantiomer; because R-warfarin has three times the anticoagulant potency of S-warfarin, its accumulation drives a rapid, large INR increase within days of fluconazole initiation
B) Fluconazole competes with warfarin for albumin-binding sites, acutely increasing the free fraction of both S- and R-warfarin; the resulting surge in unbound warfarin increases vitamin K antagonism at VKORC1 (vitamin K epoxide reductase complex 1) and rapidly elevates the INR before compensatory redistribution occurs
C) Fluconazole inhibits intestinal P-glycoprotein, increasing oral warfarin bioavailability from approximately 80% to near 100%; the resulting increase in total warfarin absorbed drives the INR elevation independent of any effect on hepatic drug metabolism
D) Fluconazole inhibits CYP2C19, which metabolizes the S-warfarin enantiomer via N-demethylation; the resulting S-warfarin accumulation explains both the magnitude of the INR increase and the rapidity of onset within four days of initiation
E) Fluconazole is a potent inhibitor of CYP2C9 (cytochrome P450 2C9), the primary enzyme responsible for hydroxylation and clearance of S-warfarin — the more pharmacologically potent enantiomer with approximately three to five times greater anticoagulant activity than R-warfarin; CYP2C9 inhibition reduces S-warfarin clearance, causing plasma S-warfarin concentrations to rise and the INR to increase 2- to 3-fold within three to five days of fluconazole initiation
ANSWER: E
Rationale:
Option E is correct. Warfarin is administered as a racemate of S- and R-enantiomers with distinct metabolic pathways and potencies. S-warfarin is approximately three to five times more pharmacologically active than R-warfarin at inhibiting VKORC1 (vitamin K epoxide reductase complex 1) and is metabolized primarily by CYP2C9 (cytochrome P450 2C9) via 7-hydroxylation. Fluconazole is a potent CYP2C9 inhibitor; co-administration reduces S-warfarin clearance, allowing S-warfarin to accumulate in plasma. Because S-warfarin is the dominant contributor to anticoagulant effect, its accumulation drives a disproportionate and rapid INR elevation — the 2- to 3-fold INR increases seen clinically typically develop within three to five days of fluconazole initiation, consistent with the four-day timeline here. This interaction is well-established and predictable; INR monitoring within three to five days of starting fluconazole in any patient on warfarin is mandatory.
Option A: Option A is incorrect; this description inverts the stereoselective pharmacology. S-warfarin (not R-warfarin) is the more pharmacologically potent enantiomer with greater anticoagulant activity, and it is CYP2C9 (not CYP3A4) that is the primary metabolic pathway for S-warfarin. R-warfarin is primarily metabolized by CYP1A2 and CYP3A4 and is less potent; fluconazole's moderate CYP3A4 inhibition does affect R-warfarin to a lesser degree but is not the primary driver of the interaction.
Option B: Option B is incorrect; protein binding displacement is a transient phenomenon and does not produce sustained, large INR elevations of the magnitude seen here. The primary mechanism of the fluconazole-warfarin interaction is metabolic (CYP2C9 inhibition), not protein binding displacement.
Option C: Option C is incorrect; warfarin oral bioavailability is already high (approximately 93 to 100%) and fluconazole does not significantly inhibit intestinal P-glycoprotein in a way that would meaningfully increase warfarin absorption.
Option D: Option D is incorrect; S-warfarin is primarily metabolized by CYP2C9, not CYP2C19. CYP2C19 plays a minor role in warfarin metabolism overall and is not the enzyme whose inhibition drives the clinically significant fluconazole-warfarin interaction.
3. A 58-year-old patient with histoplasmosis and achlorhydria secondary to autoimmune gastritis (confirmed by serum gastrin and gastric biopsy) is prescribed itraconazole capsules 200 mg twice daily. After 14 days, the itraconazole trough is undetectable. The team switches to itraconazole oral solution. Integrating the absorption mechanisms of both formulations, which statement correctly explains why the oral solution is expected to succeed where the capsule failed, and what administration instruction is essential for the solution?
A) The itraconazole oral solution uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle that pre-solubilizes the drug independent of gastric acid, making bioavailability far less dependent on intragastric pH; unlike capsules — which require acid-stimulated dissolution — the oral solution should be taken on an empty stomach (fasting state) to maximize absorption, since the cyclodextrin vehicle's solubilization is actually impaired by the presence of food-stimulated bile that competes for cyclodextrin binding
B) The itraconazole oral solution contains buffering agents that neutralize any residual gastric acid in achlorhydric patients, creating an optimal acidic microenvironment for drug dissolution at the duodenal surface; it should be taken with a full meal to maximize the buffering effect
C) The oral solution is bioequivalent to the capsule formulation in all patients regardless of gastric pH; the undetectable trough reflects poor patient adherence rather than a formulation-related absorption failure, and the solution will only succeed if adherence is confirmed
D) The oral solution achieves higher bioavailability than capsules in achlorhydric patients because it bypasses gastric absorption entirely and is absorbed exclusively in the alkaline environment of the terminal ileum, where cyclodextrin-bound drug dissociates from the vehicle and crosses the mucosal barrier
E) The oral solution is preferred in achlorhydric patients because it contains a higher itraconazole concentration per milliliter than capsules, compensating for reduced absorption by providing a higher luminal drug gradient; it should be taken with an acidic beverage such as cola to further enhance mucosal contact
ANSWER: A
Rationale:
Option A is correct. Itraconazole capsule dissolution requires gastric acid to solubilize the highly lipophilic drug from its sugar-sphere coating; in achlorhydric patients — where intragastric pH is persistently elevated — capsule dissolution is severely impaired and bioavailability can fall to near zero, explaining the undetectable trough. The itraconazole oral solution uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle that keeps itraconazole in solution independent of gastric pH, making absorption far less sensitive to achlorhydria or acid suppression. Critically, the oral solution should be taken on an empty stomach (fasting), in contrast to capsules which require food. Food and bile acids can actually compete with the cyclodextrin vehicle for lipophilic drug binding in the intestinal lumen, reducing the efficiency of cyclodextrin-facilitated absorption; the fasting state optimizes oral solution bioavailability. This fasting instruction is frequently confused with the capsule instruction (take with food) and is a clinically important distinction to convey explicitly to patients.
Option B: Option B is incorrect; the itraconazole oral solution does not contain acid-buffering agents and does not create an acidic microenvironment. The mechanism by which the solution overcomes achlorhydria is the cyclodextrin solubilizing vehicle, not pH manipulation.
Option C: Option C is incorrect; the two formulations are not bioequivalent in all patients — this is precisely the clinical scenario where they differ dramatically. Achlorhydria predictably abolishes capsule absorption while the oral solution retains adequate bioavailability. Poor adherence would be an alternative explanation, but the formulation failure is pharmacologically established and expected in achlorhydric patients.
Option D: Option D is incorrect; the oral solution is not absorbed exclusively in the terminal ileum. Absorption occurs throughout the small intestine where cyclodextrin-bound itraconazole dissociates and crosses the mucosal surface.
Option E: Option E is incorrect; the therapeutic advantage of the oral solution over capsules in achlorhydric patients is its pH-independent solubilization, not a higher drug concentration per milliliter. Administering the oral solution with an acidic beverage is not evidence-based and is not recommended.
4. A bone marrow transplant recipient develops Candida glabrata candidemia after six weeks of fluconazole prophylaxis. MIC testing shows fluconazole MIC 64 mcg/mL, voriconazole MIC 4 mcg/mL, and itraconazole MIC 2 mcg/mL. Molecular analysis reveals upregulation of CDR1 and CDR2 driven by a gain-of-function TAC1 mutation; no ERG11 point mutations are detected. How does this resistance profile differ from what would be predicted if the resistance were due exclusively to an ERG11 point mutation, and what are the treatment implications?
A) CDR1/CDR2 upregulation and ERG11 point mutations produce identical cross-resistance patterns across all azoles; the distinction between these mechanisms is academic and does not influence antifungal selection in clinical practice
B) ERG11 point mutations in C. glabrata universally confer pan-azole resistance identical to CDR1/CDR2 upregulation; therefore the absence of ERG11 mutations in this isolate indicates that the CDR1/CDR2 mechanism is less clinically significant and fluconazole at higher doses may still be effective
C) CDR1/CDR2 upregulation in C. glabrata confers fluconazole-specific resistance only, identical to the Mdr1p-mediated mechanism seen in C. albicans; voriconazole and itraconazole would therefore be expected to retain full susceptibility in this isolate
D) CDR1 and CDR2 are ABC (adenosine triphosphate-binding cassette) efflux transporters that export all azole class members — including fluconazole, voriconazole, and itraconazole — producing broad cross-azole resistance as seen in this isolate's MIC profile; by contrast, an ERG11 point mutation would more selectively impair fluconazole binding while voriconazole and itraconazole would likely retain superior activity due to their extended side chains compensating for the altered active site geometry
E) CDR1/CDR2 upregulation produces resistance to azoles and additionally confers cross-resistance to echinocandins by upregulating FKS1 (glucan synthase subunit 1) expression as a co-regulated stress response; this isolate should be assumed echinocandin-resistant and treated with liposomal amphotericin B
ANSWER: D
Rationale:
Option D is correct. CDR1 (Candida Drug Resistance 1) and CDR2 (Candida Drug Resistance 2) are ABC (adenosine triphosphate-binding cassette) transporter family members that use ATP hydrolysis to actively export azole molecules across the fungal plasma membrane. Their substrate spectrum spans the entire azole class — they transport fluconazole, voriconazole, itraconazole, and other azoles — producing cross-resistance to all class members, as reflected in this isolate's elevated MICs across all three azoles tested. In contrast, an ERG11 point mutation at a hot-spot residue such as Y132H, K143R, or F145L alters the CYP51 active site geometry in ways that primarily reduce fluconazole binding affinity; voriconazole and itraconazole, with their extended hydrophobic side chains making additional molecular contacts with CYP51 beyond the triazole nitrogen, partially compensate for the active site change and retain considerably better susceptibility. The clinical implication is that in an isolate with pure ERG11-mediated resistance, switching from fluconazole to voriconazole may restore susceptibility; in an isolate with CDR1/CDR2-mediated resistance, no azole is likely to be effective and an echinocandin should be used.
Option A: Option A is incorrect; the mechanistic distinction between CDR1/CDR2 efflux and ERG11 active site mutation predicts different cross-resistance patterns with direct clinical consequence for antifungal selection.
Option B: Option B is incorrect; ERG11 mutations in C. glabrata do not universally confer pan-azole resistance — they more characteristically impair fluconazole more than voriconazole. The resistance profile of this CDR1/CDR2-overexpressing isolate is broader than what ERG11 mutations alone would produce.
Option C: Option C is incorrect; CDR1/CDR2 confer pan-azole cross-resistance, not fluconazole-specific resistance. Mdr1p (MFS transporter, fluconazole-specific) is a distinct mechanism found primarily in C. albicans and does not describe CDR1/CDR2 function.
Option E: Option E is incorrect; CDR1/CDR2 upregulation does not co-regulate FKS1 or confer echinocandin resistance. Echinocandin resistance in C. glabrata arises from distinct FKS1 or FKS2 mutations; CDR1/CDR2 expression and FKS mutations are independent mechanisms.
5. A 68-year-old patient with end-stage renal disease (CrCl 8 mL/min, not yet on dialysis) develops cryptococcal meningitis and requires fluconazole consolidation therapy at a standard dose of 400 mg daily. Applying fluconazole's renal elimination pharmacology, which dosing strategy is most appropriate, and what is the rationale for preserving versus modifying different components of the regimen?
A) No dose adjustment is required because fluconazole clearance in severe renal impairment is compensated by upregulation of hepatic CYP3A4-mediated metabolism; plasma concentrations self-normalize within 48 to 72 hours of initiating therapy without dose modification
B) A full loading dose of 400 mg should be given on day 1 to rapidly achieve therapeutic plasma and CSF (cerebrospinal fluid) concentrations regardless of renal function; maintenance dosing should then be reduced to 200 mg daily (50% of the standard dose) because approximately 80% of fluconazole is excreted unchanged in the urine, causing half-life prolongation and drug accumulation in severe renal impairment
C) Both the loading dose and maintenance dose should be reduced by 50% simultaneously from the outset; giving a full 400 mg loading dose in severe renal impairment risks acute drug toxicity before renal elimination can occur
D) Fluconazole should be avoided entirely in patients with CrCl below 10 mL/min and replaced with intravenous amphotericin B deoxycholate, which is renally metabolized and requires no dose adjustment in end-stage renal disease
E) The maintenance dose should be reduced to 200 mg daily and the dosing interval extended to every 48 hours; the loading dose is also reduced to 200 mg because the prolonged half-life in severe renal impairment means a standard loading dose would produce supratherapeutic concentrations for more than 72 hours
ANSWER: B
Rationale:
Option B is correct. Fluconazole is excreted approximately 80% as unchanged parent drug in the urine, making renal function the primary determinant of its elimination. In severe renal impairment (CrCl below 50 mL/min), fluconazole half-life is substantially prolonged and drug accumulates with repeated standard dosing. The recommended adjustment is to give a normal loading dose on day 1 — unchanged at 400 mg in this scenario — followed by maintenance doses reduced to 50% of the standard dose (200 mg daily for the standard 400 mg regimen). The loading dose is preserved at full standard dose because its purpose is to rapidly achieve therapeutic plasma and CSF concentrations; the loading dose is a single administration whose peak concentration is determined by the dose given and the volume of distribution, not by clearance rate. Reducing the loading dose would delay achievement of therapeutic concentrations and is pharmacokinetically unjustified. Only the maintenance dose, which depends on clearance to avoid accumulation between doses, requires reduction.
Option A: Option A is incorrect; fluconazole does not have significant CYP3A4-mediated metabolism that could compensate for impaired renal clearance. Approximately 80% of the drug is eliminated unchanged renally; there is no hepatic upregulation mechanism to prevent accumulation in renal failure.
Option C: Option C is incorrect; reducing the loading dose is pharmacokinetically inappropriate. The loading dose is needed to achieve therapeutic concentrations rapidly, particularly for a serious CNS infection; its magnitude is governed by volume of distribution, not clearance. Only maintenance dosing, which determines steady-state concentrations via clearance, requires reduction.
Option D: Option D is incorrect; fluconazole is not contraindicated in patients with CrCl below 10 mL/min — it is used with dose adjustment. Amphotericin B deoxycholate is itself nephrotoxic and would be a poor choice in a patient already in end-stage renal disease.
Option E: Option E is incorrect; extending the dosing interval to every 48 hours is an alternative strategy for some renally cleared drugs, but the standard fluconazole recommendation in severe non-dialysis CKD is 50% dose reduction while maintaining the once-daily interval, not interval extension combined with a reduced loading dose.
6. A heavily pretreated patient with relapsed HIV (human immunodeficiency virus) and recurrent oropharyngeal candidiasis has received multiple courses of fluconazole and two courses of amphotericin B. A new Candida albicans isolate shows high-level resistance to all azoles tested, and amphotericin B MIC is elevated at 2 mcg/mL (above the susceptible breakpoint). Molecular analysis identifies concurrent ERG11 point mutations and ERG3 loss-of-function mutations. Integrating both resistance mechanisms, which explanation best accounts for the simultaneous azole and polyene resistance?
A) ERG11 mutations confer resistance to both azoles and amphotericin B by preventing CYP51 from producing any sterol intermediates; the total absence of membrane sterols makes the fungal membrane impermeable to both drug classes simultaneously
B) ERG3 mutations upregulate CDR1 and CDR2 efflux transporters as a compensatory stress response, pumping both azoles and amphotericin B out of the fungal cell; combined with ERG11 mutations reducing CYP51 azole binding, both drug classes are simultaneously exported before reaching their respective targets
C) ERG11 mutations reduce azole binding affinity at CYP51 (causing azole resistance), while ERG3 loss-of-function mutations prevent accumulation of toxic 14-alpha-methylated sterol intermediates (contributing to azole target bypass); simultaneously, ERG3 mutations reduce membrane ergosterol content, which is the binding target of amphotericin B, thereby reducing amphotericin B's ability to form pores in the fungal membrane and lowering its activity
D) ERG3 mutations cause compensatory overexpression of ERG11, producing excess CYP51 enzyme that both azoles and amphotericin B must compete with; the enzyme overexpression overwhelms both drug classes at therapeutic concentrations
E) The simultaneous azole and amphotericin B resistance reflects acquisition of a single master regulatory mutation in the zinc finger transcription factor Upc2p (sterol regulatory element binding protein 2 gene), which coordinately downregulates all ergosterol biosynthesis genes including ERG11 and ERG3, eliminating both the azole target and the amphotericin B binding substrate in a single genetic event
ANSWER: C
Rationale:
Option C is correct. This isolate illustrates how concurrent ERG11 and ERG3 mutations produce resistance to two pharmacologically distinct antifungal classes through converging effects on the ergosterol biosynthesis pathway. ERG11 point mutations alter key residues in the CYP51 active site, reducing azole binding affinity and conferring azole resistance by preventing adequate CYP51 inhibition at therapeutic concentrations. ERG3 loss-of-function mutations independently contribute to azole resistance by preventing conversion of 14-alpha-methylfecosterol (which accumulates during CYP51 inhibition) to toxic methylated sterol intermediates — eliminating the toxic downstream consequences of CYP51 blockade (target bypass). Critically, ERG3 mutations also reduce total cellular ergosterol content in the fungal membrane because the normal ERG3-mediated sterol desaturation step is required for full ergosterol synthesis. Amphotericin B acts by binding ergosterol in the fungal membrane and forming pores that disrupt ion gradients; reduced membrane ergosterol content diminishes the drug's target availability and membrane disruption capacity, explaining the elevated amphotericin B MIC. This mechanistic convergence — where pathway mutations affect both drug class targets — creates a clinically dangerous situation with limited therapeutic options.
Option A: Option A is incorrect; ERG11 mutations reduce azole binding affinity but do not abolish sterol synthesis or eliminate membrane sterols. CYP51 retains catalytic function; ergosterol synthesis continues (via an altered intermediate profile), and the membrane retains sterol content.
Option B: Option B is incorrect; ERG3 mutations do not upregulate CDR1/CDR2 efflux transporters as a stress response, and CDR1/CDR2 transporters do not export amphotericin B — amphotericin B is a large polyene molecule that acts at the membrane surface, not a substrate for these intracellular efflux pumps.
Option D: Option D is incorrect; ERG3 mutations do not cause compensatory overexpression of ERG11. ERG3 and ERG11 are independently regulated genes in the ergosterol pathway.
Option E: Option E is incorrect; simultaneous loss-of-function of both ERG11 and ERG3 through a single Upc2p transcriptional event is not the established mechanism here. Upc2p mutations are associated with ERG11 upregulation (increasing CYP51 quantity), not with coordinate loss-of-function across multiple ERG genes.
7. A patient with pulmonary histoplasmosis is receiving itraconazole oral solution 200 mg twice daily. After 14 days, the steady-state combined itraconazole plus hydroxy-itraconazole trough is 1.4 mcg/mL — above the 1.0 mcg/mL treatment threshold. However, the treating clinician wonders whether the plasma concentration accurately reflects drug exposure at the site of infection in the lungs. Applying itraconazole's volume of distribution and tissue distribution pharmacokinetics, which statement best characterizes the relationship between plasma TDM and pulmonary drug exposure?
A) Plasma itraconazole trough concentrations reliably reflect pulmonary tissue concentrations because the lung is a well-perfused organ with rapid equilibration between plasma and tissue compartments; a trough of 1.4 mcg/mL predicts equivalent lung tissue concentrations
B) Plasma TDM overestimates pulmonary drug exposure in itraconazole therapy because the lung tissue protein-binding environment differs from plasma; pulmonary concentrations are consistently lower than simultaneous plasma concentrations by a factor of approximately 3 to 5
C) Plasma TDM is irrelevant for itraconazole because the drug is entirely eliminated via biliary secretion into the lung airway lining fluid before reaching the systemic circulation; lung concentrations are therefore independent of plasma measurements
D) Plasma TDM is the only valid measure of itraconazole exposure because the large volume of distribution means all tissue concentrations are freely reversible with plasma; tissue concentrations rise and fall in direct proportion to plasma concentrations at all times
E) Itraconazole's large volume of distribution of approximately 11 L/kg reflects massive accumulation in lipophilic tissues including lung, skin, and nails, where concentrations can exceed simultaneous plasma concentrations by 10- to 100-fold; plasma TDM therefore substantially underestimates pulmonary drug exposure, and a trough above the 1.0 mcg/mL plasma threshold likely corresponds to substantially higher lung tissue concentrations that are pharmacodynamically adequate at the site of infection
ANSWER: E
Rationale:
Option E is correct. Itraconazole's volume of distribution of approximately 11 L/kg is one of the largest among systemic antifungals, reflecting extensive binding to lipophilic tissue proteins and accumulation in highly lipophilic tissues. In lung tissue specifically, itraconazole concentrations typically exceed simultaneous plasma concentrations by factors of 10 to 100 or more; similar relationships hold for skin, nails, liver, and adipose tissue. This means that a plasma trough of 1.4 mcg/mL in this patient likely corresponds to pulmonary tissue concentrations many-fold higher — potentially 14 to 140 mcg/g or higher — well above what would be required for antifungal efficacy against Histoplasma capsulatum. The practical implication is that plasma TDM, while essential for confirming adequate oral absorption and systemic drug exposure, actually underestimates tissue drug concentrations at lipophilic sites. This pharmacokinetic property contributes to itraconazole's clinical effectiveness for pulmonary and dermatologic fungal infections even when plasma concentrations appear modestly above threshold. The important caveat is the opposite: at sites with poor drug accumulation (CNS, urine, aqueous humor), tissue concentrations may fall below plasma concentrations.
Option A: Option A is incorrect; lung tissue concentrations are not equivalent to simultaneous plasma concentrations for itraconazole. Due to its high lipophilicity and protein binding to tissue proteins, itraconazole concentrates in lung tissue far above plasma levels.
Option B: Option B is incorrect; this reverses the relationship. Plasma TDM underestimates pulmonary drug exposure for itraconazole, not overestimates. Lung concentrations are substantially higher than plasma concentrations, not lower.
Option C: Option C is incorrect; itraconazole is not eliminated via biliary secretion into airway lining fluid. Its pulmonary accumulation is pharmacokinetic (partitioning into lipophilic lung tissue from systemic circulation), not secretory.
Option D: Option D is incorrect; the large volume of distribution does not mean tissue concentrations rise and fall in direct proportion to plasma at all times. Deep tissue compartments equilibrate slowly with plasma; during steady state, tissue concentrations at lipophilic sites substantially exceed plasma concentrations rather than tracking proportionally.
8. An ICU (intensive care unit) attending is reviewing the antifungal resistance profiles of three Candida species identified in blood cultures from three different patients this week: Candida krusei, Candida glabrata, and Candida auris. Integrating the resistance mechanisms and clinical implications for each species, which statement most accurately differentiates the azole resistance pattern and prescribing response appropriate for each?
A) Candida krusei has intrinsic fluconazole resistance present in all isolates regardless of prior azole exposure, with voriconazole and echinocandins retaining activity; Candida glabrata has variable azole resistance (10 to 30% fluconazole-resistant isolates in many centers, driven by CDR1/CDR2 efflux) requiring susceptibility testing before azole use; Candida auris frequently displays simultaneous resistance to multiple azole class members including voriconazole and posaconazole (pan-azole resistance), making mandatory susceptibility testing essential before any antifungal selection and echinocandins the preferred empirical treatment
B) All three species share an identical mechanism of fluconazole resistance — ERG11 point mutation at the Y132H hot spot — but differ in whether the resistance is intrinsic or acquired; susceptibility testing is therefore unnecessary because all three require echinocandin treatment regardless of testing results
C) Candida krusei and Candida auris are both uniformly pan-azole resistant with no intra-species variability; Candida glabrata has intrinsic fluconazole resistance but retains reliable susceptibility to voriconazole and itraconazole, which can be used without susceptibility testing in all C. glabrata infections
D) Susceptibility testing is only clinically necessary for Candida auris; for Candida krusei and Candida glabrata, the resistance pattern is sufficiently predictable that empirical fluconazole therapy is safe while awaiting formal identification to species level
E) Candida glabrata and Candida auris share pan-azole resistance that is uniformly present at baseline without prior antifungal exposure; Candida krusei retains susceptibility to voriconazole and itraconazole only in treatment-naive patients, with pan-azole resistance emerging predictably after more than 14 days of any azole therapy
ANSWER: A
Rationale:
Option A is correct. The three species have distinct resistance profiles that require differentiated clinical responses. Candida krusei (Pichia kudriavzevii) has intrinsic fluconazole resistance present in all isolates from the outset, mediated by low-affinity CYP51 and constitutive CDR efflux; voriconazole retains activity and echinocandins are first-line for invasive disease. Candida glabrata (Nakaseomyces glabratae) has variable azole resistance, with fluconazole resistance rates of 10 to 30% in many centers driven primarily by CDR1/CDR2 efflux upregulation, but not uniform — susceptibility testing is required before any azole use, and echinocandins are the empirical first-line choice pending results. Candida auris represents a qualitatively different threat: it frequently displays simultaneous resistance to fluconazole, voriconazole, itraconazole, and posaconazole (pan-azole resistance) at baseline, with additional amphotericin B resistance occurring in some isolates; susceptibility testing is mandatory for every isolate and for every antifungal class being considered, and echinocandins are preferred empirically. The key clinical distinction is that C. auris pan-azole resistance extends beyond fluconazole to include extended-spectrum azoles, a feature not consistently present in C. krusei or C. glabrata.
Option B: Option B is incorrect; the three species do not share an identical resistance mechanism, and Y132H is specifically a C. albicans ERG11 hot-spot mutation. C. krusei resistance is mechanism-distinct (intrinsic low-affinity CYP51 plus efflux), and C. auris resistance is multimechanistic. Susceptibility testing is essential, particularly for C. glabrata and C. auris.
Option C: Option C is incorrect; C. glabrata does not have intrinsic fluconazole resistance — its resistance is variable and present in only 10 to 30% of isolates. C. glabrata cannot be treated with voriconazole or itraconazole without susceptibility testing since cross-resistance via CDR1/CDR2 is common.
Option D: Option D is incorrect; empirical fluconazole is not safe for C. krusei (intrinsically resistant) or C. glabrata (high resistance rates enriched by prior prophylaxis exposure) regardless of whether formal susceptibility testing is pending.
Option E: Option E is incorrect; C. glabrata resistance is variable, not uniformly present at baseline, and C. krusei does not develop pan-azole resistance after 14 days of azole therapy — its intrinsic fluconazole resistance is mechanistically fixed from the outset and unrelated to therapy duration.
9. A 34-year-old patient with HIV (human immunodeficiency virus) is receiving rifampin, isoniazid, pyrazinamide, and ethambutol for smear-positive pulmonary tuberculosis. He now has serologic and culture evidence of disseminated histoplasmosis. The team wishes to use itraconazole but is aware of the rifampin interaction. Integrating the molecular mechanism of the interaction with practical clinical management, which approach best addresses the concurrent treatment of both infections?
A) Increase the itraconazole oral solution dose to 400 mg three times daily; pharmacokinetic studies show that tripling the itraconazole dose reliably overcomes rifampin-induced CYP3A4 induction and achieves therapeutic trough concentrations above 1.0 mcg/mL in most patients on rifampin-based TB therapy
B) Administer itraconazole and rifampin six hours apart to prevent luminal drug interaction; separating the administration times abolishes the CYP3A4 induction effect and allows standard itraconazole dosing of 200 mg twice daily to achieve therapeutic concentrations
C) Switch from itraconazole to fluconazole for histoplasmosis treatment; fluconazole is minimally affected by rifampin-induced CYP3A4 induction because its primary clearance is via CYP2C9-independent renal excretion of unchanged drug, making it a reliable substitute when rifampin cannot be discontinued
D) The rifampin-itraconazole combination is essentially contraindicated because rifampin activates the pregnane X receptor (PXR), massively upregulating both intestinal and hepatic CYP3A4 expression and reducing itraconazole concentrations to near zero; clinical management requires either substituting amphotericin B for histoplasmosis treatment during the rifampin-intensive TB phase, or replacing rifampin with a rifampin-sparing TB regimen in consultation with infectious disease specialists
E) Discontinue all azole antifungals and treat histoplasmosis exclusively with an echinocandin; echinocandins have no CYP3A4 interactions with rifampin and are equally effective as itraconazole for disseminated histoplasmosis treatment
ANSWER: D
Rationale:
Option D is correct. Rifampin is among the most potent inducers of CYP3A4 in clinical pharmacology, acting through activation of the pregnane X receptor (PXR), a nuclear receptor that upregulates CYP3A4 transcription in both the intestinal wall and hepatocytes. Itraconazole is primarily metabolized by CYP3A4; the combination of increased first-pass intestinal metabolism (reducing oral bioavailability) and accelerated hepatic clearance can reduce itraconazole plasma concentrations to near zero — an effect well-documented in pharmacokinetic studies. Simply increasing the itraconazole dose has been studied but does not reliably achieve therapeutic concentrations in the presence of full-dose rifampin. Separating administration times has no effect because CYP3A4 induction is a sustained transcriptional process, not a competitive luminal interaction. The clinically sound approaches are: (1) treat histoplasmosis with liposomal or conventional amphotericin B during the rifampin-intensive TB treatment phase, transitioning to itraconazole step-down once rifampin is discontinued; or (2) modify the TB regimen with infectious disease consultation — substituting rifabutin for rifampin (where available and appropriate), as rifabutin is a less potent CYP3A4 inducer that allows higher itraconazole concentrations, though the interaction is not eliminated.
Option A: Option A is incorrect; dose tripling of itraconazole does not reliably overcome rifampin-induced CYP3A4 induction in most patients. Pharmacokinetic data show that even at 400 mg twice daily, itraconazole concentrations remain subtherapeutic in many patients on full-dose rifampin; this strategy is not a validated clinical approach.
Option B: Option B is incorrect; rifampin-induced CYP3A4 induction is a transcriptional effect on enzyme expression, not a luminal drug-drug interaction. Separating administration times by six hours does not affect the sustained CYP3A4 induction that operates continuously.
Option C: Option C is incorrect; while fluconazole is primarily renally excreted as unchanged drug and is less affected by CYP3A4 induction than itraconazole, it is not a reliable substitute for histoplasmosis. Fluconazole has inferior activity against Histoplasma capsulatum compared to itraconazole and is not recommended for histoplasmosis treatment in current guidelines; its use is restricted to specific clinical contexts where itraconazole cannot be administered.
Option E: Option E is incorrect; echinocandins do not have established efficacy for disseminated histoplasmosis. Histoplasma capsulatum has intrinsic resistance to echinocandins; these agents are not an appropriate treatment for this infection.
10. A 55-year-old woman receiving methadone 120 mg daily for opioid use disorder and furosemide for heart failure is started on fluconazole 400 mg daily for cryptococcal meningitis consolidation. Her baseline ECG (electrocardiogram) shows QTc 448 ms and serum potassium is 3.1 mEq/L. Three days later the QTc is 532 ms. Integrating the distinct mechanisms by which each factor contributes to QTc prolongation in this patient, which explanation is most complete?
A) The QTc prolongation results entirely from fluconazole-induced CYP3A4 inhibition raising methadone plasma concentrations; electrolyte status and direct fluconazole cardiac effects play no role and correction of hypokalemia alone will normalize the QTc
B) Three independent mechanisms converge to prolong the QTc: fluconazole directly blocks the hERG (human ether-a-go-go-related gene) channel reducing IKr (rapid delayed rectifier potassium current); fluconazole moderately inhibits CYP3A4, increasing methadone plasma concentrations — methadone is itself a potent hERG channel blocker adding to IKr suppression; and hypokalemia reduces the extracellular potassium driving force for IKr channel recovery, amplifying the degree of hERG block from both drugs — all three mechanisms are additive and require simultaneous management
C) Methadone-induced QTc prolongation is independent of plasma concentration in patients on stable chronic dosing; the QTc increase is caused entirely by fluconazole's direct hERG blockade alone, and methadone should not be dose-adjusted in response to starting fluconazole
D) Furosemide causes hypokalemia, which activates L-type calcium channels in ventricular cardiomyocytes; fluconazole inhibits the CYP3A4-mediated metabolism of furosemide, raising furosemide concentrations and worsening potassium loss — the resulting severe hypokalemia is the sole mechanism of QTc prolongation, with neither fluconazole nor methadone having direct cardiac electrophysiological effects
E) The QTc prolongation in this patient is caused by fluconazole's inhibition of CYP2C9, the enzyme responsible for cardiac potassium channel protein synthesis; CYP2C9 inhibition reduces IKr channel expression over three days, prolonging the QTc through a transcriptional mechanism rather than direct channel blockade
ANSWER: B
Rationale:
Option B is correct. Three mechanistically distinct but additive processes converge in this patient. First, fluconazole directly blocks the hERG (human ether-a-go-go-related gene) potassium channel, which underlies the rapid delayed rectifier potassium current (IKr) responsible for phase 3 ventricular repolarization; this effect is dose-dependent and most prominent at 400 mg daily or above. Second, fluconazole moderately inhibits CYP3A4 — the primary enzyme for methadone N-demethylation — raising methadone plasma concentrations; methadone itself is a potent hERG channel blocker, so elevated methadone levels compound the degree of IKr suppression already caused by fluconazole directly. Third, hypokalemia reduces the extracellular potassium concentration, which normally supports hERG channel recovery from inactivation; lower extracellular potassium increases the effective potency of hERG-blocking drugs, amplifying the IKr suppression produced by both fluconazole and methadone at a given plasma concentration. All three mechanisms are pharmacologically additive and each contributes independently to the 84 ms QTc increase observed. Management requires addressing each simultaneously: ECG monitoring, potassium repletion to above 4.0 mEq/L, consideration of methadone dose reduction or substitution, and reassessment of whether fluconazole's benefit justifies the combined QTc risk.
Option A: Option A is incorrect; CYP3A4-mediated methadone elevation is a contributing mechanism but not the sole one. Fluconazole's direct hERG block and the amplifying effect of hypokalemia are independent contributors that cannot be dismissed; correcting hypokalemia alone will not normalize the QTc when both drug-mediated hERG blocks remain.
Option C: Option C is incorrect; methadone QTc risk is plasma concentration-dependent; even in stable chronic dosing patients, raising methadone concentrations via CYP3A4 inhibition increases hERG block and prolongs the QTc. Methadone dose adjustment in response to CYP3A4 inhibitor initiation is clinically indicated.
Option D: Option D is incorrect; fluconazole does not inhibit CYP3A4-mediated furosemide metabolism to a clinically meaningful degree (furosemide is not a significant CYP3A4 substrate), and neither fluconazole nor methadone causes QTc prolongation through L-type calcium channel activation — both agents act on the hERG repolarizing potassium channel.
Option E: Option E is incorrect; CYP2C9 does not control cardiac potassium channel protein synthesis. QTc prolongation from fluconazole occurs through direct hERG channel blockade, not via a CYP2C9-mediated transcriptional reduction in IKr channel expression.
11. A 46-year-old HIV-positive patient with a CD4 count of 55 cells/mcL develops disseminated histoplasmosis not requiring amphotericin B induction. He takes omeprazole 40 mg daily for peptic ulcer disease, tenofovir/emtricitabine/dolutegravir for antiretroviral therapy, and trimethoprim-sulfamethoxazole prophylaxis. The team initiates itraconazole oral solution 200 mg twice daily. Integrating formulation pharmacokinetics, administration instructions, and monitoring strategy, which multi-step plan is most appropriate?
A) Switch to itraconazole capsules because the oral solution's cyclodextrin vehicle interacts with omeprazole to form an insoluble complex in the stomach; take capsules with a full meal and an acidic beverage, obtain trough concentrations on day 7, and target above 0.5 mcg/mL for treatment
B) Continue itraconazole oral solution, administer it simultaneously with omeprazole to allow the alkaline gastric pH created by omeprazole to optimize cyclodextrin vehicle dissociation in the duodenum; obtain trough on day 3 and adjust dose based on the result
C) Discontinue omeprazole entirely before starting itraconazole oral solution; without acid suppression, the oral solution achieves superior bioavailability compared to its performance with any PPI co-administration, and trough monitoring is unnecessary if omeprazole is stopped
D) Switch to fluconazole 400 mg daily as it is unaffected by omeprazole, achieves reliable bioavailability, requires no food or pH conditions for absorption, and is the guideline-preferred first-line agent for disseminated histoplasmosis in HIV-positive patients with CD4 counts below 100
E) Continue itraconazole oral solution — its hydroxypropyl-beta-cyclodextrin vehicle provides absorption that is far less dependent on gastric pH than capsules, making omeprazole co-administration acceptable; administer the solution on an empty stomach (fasting) for optimal absorption; obtain a combined itraconazole plus hydroxy-itraconazole trough at steady state after 14 days and confirm it is above 1.0 mcg/mL for treatment of invasive infection
ANSWER: E
Rationale:
Option E is correct. This question integrates three distinct pharmacokinetic principles that must all be applied correctly. First, formulation selection: itraconazole oral solution uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle that pre-solubilizes the drug independent of gastric pH, making it far less susceptible than capsules to the acid-suppressing effect of omeprazole. Switching to capsules would be incorrect — capsules require acid for dissolution and would perform poorly in this patient on omeprazole. Second, administration instruction: itraconazole oral solution should be taken on an empty stomach (fasting state), in deliberate contrast to capsules which require food. Food and bile can compete with cyclodextrin for lipophilic drug binding, and the fasting instruction optimizes oral solution bioavailability. Third, TDM timing and target: itraconazole has a half-life of 24 to 42 hours (extending further with prolonged therapy), requiring approximately 14 days to reach steady state; trough concentrations drawn before steady state will underestimate eventual exposure. The therapeutic target for treatment of invasive infection is a combined itraconazole plus hydroxy-itraconazole trough above 1.0 mcg/mL.
Option A: Option A is incorrect on multiple grounds: the oral solution should not be switched to capsules (capsules are highly pH-dependent and would perform poorly with omeprazole); the cyclodextrin vehicle does not interact with omeprazole to form an insoluble complex; and day-7 trough monitoring predates steady state and would be uninterpretable.
Option B: Option B is incorrect; simultaneous administration of the oral solution with omeprazole is not the rationale for the solution's pH-independence advantage. The oral solution should be taken on an empty stomach, not simultaneously with another medication, and day-3 concentrations are far from steady state.
Option C: Option C is incorrect; discontinuing omeprazole is not necessary when using the oral solution, and the oral solution does not require acid suppression discontinuation to achieve adequate bioavailability. Additionally, omeprazole discontinuation may be clinically inappropriate for a patient with peptic ulcer disease.
Option D: Option D is incorrect; fluconazole is not the guideline-preferred first-line agent for histoplasmosis. Itraconazole is the drug of choice for mild-to-moderate histoplasmosis per IDSA guidelines; fluconazole has inferior activity against Histoplasma capsulatum.
12. A patient with HIV (human immunodeficiency virus) and relapsing oropharyngeal candidiasis has failed fluconazole 200 mg daily after four weeks of therapy. The Candida albicans isolate has fluconazole MIC 128 mcg/mL, voriconazole MIC 0.06 mcg/mL, and itraconazole MIC 0.12 mcg/mL. Molecular analysis identifies upregulated MDR1 expression driven by a gain-of-function MRR1 (multidrug resistance regulator 1 gene) mutation; ERG11 sequencing reveals no point mutations and CDR1/CDR2 expression is not elevated. Applying the substrate specificity of the Mdr1p transporter, which treatment decision is most mechanistically justified?
A) Switch to high-dose fluconazole 800 mg daily; MRR1-driven MDR1 upregulation is dose-inducible and reaches a maximum transport capacity that is saturable at higher drug concentrations, allowing supratherapeutic fluconazole concentrations to overcome the efflux mechanism
B) Switch to an echinocandin; MDR1 upregulation in C. albicans is consistently accompanied by upregulation of FKS1 (glucan synthase subunit 1) as part of a coordinated multidrug resistance response, making echinocandins the only reliable option when MDR1 is overexpressed
C) Switch to voriconazole; the Mdr1p transporter is a member of the major facilitator superfamily (MFS) with substrate specificity predominantly for fluconazole rather than voriconazole or itraconazole — the voriconazole MIC of 0.06 mcg/mL confirms retained susceptibility, and a mechanistic switch to voriconazole is appropriate because the resistance mechanism does not export voriconazole
D) Continue fluconazole but add a P-glycoprotein inhibitor such as itraconazole to block the Mdr1p transporter; combining fluconazole with an MFS transporter inhibitor restores intracellular fluconazole concentrations to therapeutic levels without requiring a change in the primary antifungal agent
E) Switch to itraconazole; itraconazole is a potent CYP3A4 inhibitor that indirectly inhibits Mdr1p transporter activity by reducing the ATP (adenosine triphosphate) available to power the efflux pump, rendering the MDR1-mediated resistance mechanism inactive at standard itraconazole doses
ANSWER: C
Rationale:
Option C is correct. The Mdr1p transporter encoded by MDR1 is a member of the major facilitator superfamily (MFS) of drug efflux transporters that uses the proton motive force for energy — mechanistically distinct from the ABC (adenosine triphosphate-binding cassette) transporters CDR1 and CDR2. The critical clinical point is that Mdr1p has substrate specificity predominantly for fluconazole within the azole class; it does not efficiently export voriconazole or itraconazole. Gain-of-function MRR1 mutations constitutively activate MDR1 expression, producing fluconazole-selective resistance. The susceptibility data for this isolate — fluconazole MIC 128 mcg/mL versus voriconazole MIC 0.06 mcg/mL — are mechanistically consistent with MDR1-mediated efflux selectively removing fluconazole while voriconazole concentrations inside the fungal cell remain unaffected. Switching to voriconazole is directly supported by the mechanism: the resistance gene does not export voriconazole, the voriconazole MIC is within the susceptible range, and no ERG11 mutations are present that would reduce voriconazole CYP51 binding. This case illustrates the clinical value of characterizing the specific resistance mechanism rather than empirically escalating to echinocandin therapy.
Option A: Option A is incorrect; Mdr1p-mediated efflux is not saturable by dose escalation in a clinically achievable range. The transporter is constitutively overexpressed due to a gain-of-function MRR1 mutation; the MIC of 128 mcg/mL is far above achievable fluconazole plasma concentrations, and dose escalation to 800 mg daily would not overcome the efflux capacity.
Option B: Option B is incorrect; MDR1 upregulation does not co-induce FKS1 overexpression or confer echinocandin resistance. These are independent mechanisms; the CDR/MDR and FKS resistance pathways are not co-regulated.
Option D: Option D is incorrect; Mdr1p is an MFS transporter, not a P-glycoprotein. Itraconazole inhibits P-glycoprotein (an ABC transporter), not MFS transporters; this combination would not restore intracellular fluconazole concentrations.
Option E: Option E is incorrect; itraconazole's CYP3A4 inhibition has no effect on Mdr1p transporter function. Mdr1p uses the proton motive force, not ATP; even if ATP availability were reduced, this would not specifically inhibit Mdr1p. This mechanism is pharmacologically fabricated.
13. A 64-year-old man with ischemic cardiomyopathy (ejection fraction 22%), NYHA class III heart failure on guideline-directed medical therapy, and type 2 diabetes develops moderately severe disseminated histoplasmosis with positive urine and serum Histoplasma antigen but no respiratory failure. His clinical team wishes to treat with itraconazole oral solution but is concerned about cardiac risk. Integrating itraconazole's cardiac pharmacology with the available antifungal landscape for histoplasmosis, which management plan is most appropriate?
A) Itraconazole is formally contraindicated in this patient due to its negative inotropic effect and FDA (Food and Drug Administration) black-box warning against use in patients with evidence of ventricular dysfunction; for moderately severe disseminated histoplasmosis, treatment should be initiated with liposomal amphotericin B for induction followed by step-down to a non-itraconazole azole — however, fluconazole has inferior Histoplasma activity and voriconazole may be considered as a step-down option in consultation with infectious disease specialists if itraconazole cannot be used after induction
B) Itraconazole can be used safely in heart failure patients at doses below 200 mg daily because the negative inotropic effect is dose-dependent and does not occur below the 400 mg daily threshold; prescribe 100 mg daily with weekly echocardiographic monitoring
C) Itraconazole's negative inotropy is only clinically relevant in patients with EF (ejection fraction) below 15%; with an EF of 22%, the cardiac risk is subclinical and itraconazole oral solution 200 mg twice daily can be used with monthly echocardiographic surveillance
D) Replace itraconazole with high-dose fluconazole 800 mg daily, which has equivalent efficacy to itraconazole for disseminated histoplasmosis, no cardiac contraindications in heart failure patients, and is the IDSA (Infectious Diseases Society of America) guideline-preferred alternative when itraconazole is contraindicated
E) The negative inotropic effect of itraconazole can be mitigated by adding dobutamine as a positive inotropic agent during itraconazole therapy; this combination allows itraconazole to be used safely in patients with ejection fractions as low as 20% while avoiding the nephrotoxicity of amphotericin B
ANSWER: A
Rationale:
Option A is correct. Itraconazole has a documented negative inotropic effect on the myocardium — it reduces cardiac contractility — and the FDA prescribing information includes a contraindication for its use in patients with evidence of ventricular dysfunction, including congestive heart failure or a history of heart failure. With an ejection fraction of 22% and NYHA class III symptoms, this patient meets the formal contraindication criteria. For moderately severe disseminated histoplasmosis — characterized by positive antigen testing and systemic involvement but no respiratory failure or shock — the IDSA guidelines recommend liposomal amphotericin B for induction of moderate-to-severe cases, with step-down to an azole once clinical improvement is established. When itraconazole cannot be used for step-down, the alternatives are limited: fluconazole has substantially inferior activity against Histoplasma capsulatum and is not guideline-preferred; voriconazole has been used in case reports and small series as an alternative in patients who cannot receive itraconazole, and represents a reasonable option in consultation with infectious disease specialists despite not being a primary guideline recommendation.
Option B: Option B is incorrect; itraconazole's negative inotropic effect is not dose-dependent in the sense of having a safe sub-threshold dose below 200 mg daily. The FDA contraindication applies to all doses in patients with ventricular dysfunction, not just doses above 400 mg daily. There is no established safe dose of itraconazole in this patient population.
Option C: Option C is incorrect; the FDA contraindication for itraconazole in ventricular dysfunction is not restricted to patients with EF below 15%. The contraindication applies broadly to evidence of ventricular dysfunction, and an EF of 22% with symptomatic heart failure clearly falls within this category.
Option D: Option D is incorrect; fluconazole does not have equivalent efficacy to itraconazole for disseminated histoplasmosis. Fluconazole is not the IDSA-preferred alternative for histoplasmosis when itraconazole is contraindicated; it is considered inferior and is typically reserved for patients who cannot tolerate any other agent.
Option E: Option E is incorrect; combining itraconazole with dobutamine to offset its negative inotropy is not an established or evidence-based clinical strategy. This approach does not appear in guidelines or pharmacological literature as a management option for itraconazole use in heart failure.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.